A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

ClinicalTrials.gov ID: NCT00504270

Public ClinicalTrials.gov record NCT00504270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Study identification

NCT ID: NCT00504270
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 66 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

Placebo Drug
RG3421 120mg Drug
RG3421 20mg Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2007
Primary completion: Aug 31, 2009
Completion: Aug 31, 2009
Last update posted: Nov 1, 2016

2007 – 2009

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Not listed	Hot Springs	Arkansas	71913	—
Not listed	Little Rock	Arkansas	72205	—
Not listed	Santa Monica	California	90404	—
Not listed	Alpharetta	Georgia	30005	—
Not listed	East Windsor	New Jersey	08520	—
Not listed	Albuquerque	New Mexico	87106	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10029	—
Not listed	Stony Brook	New York	11790	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Providence	Rhode Island	02903	—
Not listed	Nashville	Tennessee	37215	—
Not listed	Galveston	Texas	77550	—
Not listed	San Antonio	Texas	78229	—
Not listed	Webster	Texas	77598	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00504270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00504270 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →